Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
The Oral route of administration segment is anticipated to be the fastest-growing category with a CAGR of 10.2% from 2026 to 2033, driven by growing patient preference for non-injectable therapies, improving treatment compliance, and ongoing advancements in oral peptide drug delivery technologies
Shortly after Ozempic gained approval, Novo Nordisk conducted a 68-week randomized, double-blind, placebo-controlled trial in participants without type 2 diabetes
However, a notable side effect was observed: MT-II-treated normal C57BL/6J mice exhibited significant weight loss, with their average weight decreasing from a baseline of 30.9 1.4 grams to 26.5 1.7 grams after the 14-day treatment course, a change not seen in vehicle-treated controls
10.1016/j.jff.2024.106355 93 TariqH.AsifS.AndleebA.HanoC.AbbasiB
US$ 22.53
US$ 20.75
US$ 28.44
